These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 23973701

  • 21. Doses of renin-angiotensin system inhibitors but not beta-blockers predict outcome after ST-elevation myocardial infarction.
    Liu PY, Chen CL, Yu MC, Ko YL, Hsu SY, Chou HH, Yeh KH, Duan DM, Chen MH, Lin JF.
    Acta Clin Belg; 2019 Oct; 74(5):334-341. PubMed ID: 30295167
    [Abstract] [Full Text] [Related]

  • 22. Impact of renin angiotensin system inhibitor on 3-year clinical outcomes in acute myocardial infarction patients with preserved left ventricular systolic function: a prospective cohort study from Korea Acute Myocardial Infarction Registry (KAMIR).
    Kim KH, Choi BG, Rha SW, Choi CU, Jeong MH, Other KAMIR-NIH investigators.
    BMC Cardiovasc Disord; 2021 May 21; 21(1):251. PubMed ID: 34020593
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of discharge prescriptions for secondary prevention in patients with acute coronary syndromes in Iraq.
    Nassr OA, Forsyth P, Johnson CF.
    Pharm Pract (Granada); 2019 May 21; 17(1):1372. PubMed ID: 31015874
    [Abstract] [Full Text] [Related]

  • 24. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry.
    Song PS, Seol SH, Seo GW, Kim DK, Kim KH, Yang JH, Hahn JY, Gwon HC, Ahn Y, Jeong MH, Song YB, Kim DI, Other Korean Working Group in Myocardial Infarction Registry Investigators.
    Am J Cardiovasc Drugs; 2015 Dec 21; 15(6):439-49. PubMed ID: 26153396
    [Abstract] [Full Text] [Related]

  • 25. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients.
    Choudhry NK, Setoguchi S, Levin R, Winkelmayer WC, Shrank WH.
    Pharmacoepidemiol Drug Saf; 2008 Dec 21; 17(12):1189-96. PubMed ID: 18956426
    [Abstract] [Full Text] [Related]

  • 26. Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases.
    Neumann A, Maura G, Weill A, Alla F, Danchin N.
    Circ Cardiovasc Qual Outcomes; 2018 Apr 21; 11(4):e004356. PubMed ID: 29653999
    [Abstract] [Full Text] [Related]

  • 27. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
    Barron HV, Michaels AD, Maynard C, Every NR.
    J Am Coll Cardiol; 1998 Aug 21; 32(2):360-7. PubMed ID: 9708461
    [Abstract] [Full Text] [Related]

  • 28. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction.
    Evans M, Carrero JJ, Szummer K, Åkerblom A, Edfors R, Spaak J, Jacobson SH, Andell P, Lindhagen L, Jernberg T.
    J Am Coll Cardiol; 2016 Apr 12; 67(14):1687-97. PubMed ID: 27056774
    [Abstract] [Full Text] [Related]

  • 29. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G, Annis IE, Farley JF, Mahendraratnam N, Hickson RP, Stürmer T, Robinson JG.
    Pharmacotherapy; 2018 Jan 12; 38(1):29-41. PubMed ID: 29059475
    [Abstract] [Full Text] [Related]

  • 30. Variability of discharge medical therapy for secondary prevention among patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) in the United States.
    Smilowitz NR, Dubner R, Hellkamp AS, Widmer RJ, Reynolds HR.
    PLoS One; 2021 Jan 12; 16(8):e0255462. PubMed ID: 34339469
    [Abstract] [Full Text] [Related]

  • 31. Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial.
    Fanaroff AC, Peterson ED, Kaltenbach LA, Cannon CP, Choudhry NK, Henry TD, Anstrom KJ, Cohen DJ, Fonseca E, Khan ND, Fonarow GC, Wang TY.
    JAMA Cardiol; 2020 Jan 01; 5(1):38-46. PubMed ID: 31721978
    [Abstract] [Full Text] [Related]

  • 32. Association of Diabetes Mellitus Status and Glycemic Control With Secondary Prevention Medication Adherence After Acute Myocardial Infarction.
    Adamek KE, Ramadurai D, Gunzburger E, Plomondon ME, Ho PM, Raghavan S.
    J Am Heart Assoc; 2019 Feb 05; 8(3):e011448. PubMed ID: 30712488
    [Abstract] [Full Text] [Related]

  • 33. Patterns of 12-Month Post-Myocardial Infarction Medication Use According to Revascularisation Strategy: Analysis of 15,339 Admissions in Victoria, Australia.
    Livori AC, Ademi Z, Ilomäki J, Nelson AJ, Bell JS, Morton JI.
    Heart Lung Circ; 2024 Oct 05; 33(10):1439-1449. PubMed ID: 38964944
    [Abstract] [Full Text] [Related]

  • 34. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M, Fonarow GC, Peterson ED, TRANSLATE-ACS Study Investigators.
    Am Heart J; 2015 Jul 05; 170(1):62-9. PubMed ID: 26093865
    [Abstract] [Full Text] [Related]

  • 35. Passive Prescription of Secondary Prevention Medical Therapy during Index Hospitalization for Acute Myocardial Infarction Is Prevalent and Associated with Adverse Clinical Outcomes.
    Xurui Huang N, Sanderson JE, Fang F, Yu CM, Yan BP.
    J Healthc Eng; 2021 Jul 05; 2021():9543912. PubMed ID: 34976331
    [Abstract] [Full Text] [Related]

  • 36. The impact of in-hospital cardiac rehabilitation program on medication adherence and clinical outcomes in patients with acute myocardial infarction in the Lazio region of Italy.
    Soldati S, Di Martino M, Rosa AC, Fusco D, Davoli M, Mureddu GF.
    BMC Cardiovasc Disord; 2021 Sep 27; 21(1):466. PubMed ID: 34565326
    [Abstract] [Full Text] [Related]

  • 37. Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction.
    Chrischilles EA, Schneider KM, Schroeder MC, Letuchy E, Wallace RB, Robinson JG, Brooks JM.
    J Am Geriatr Soc; 2016 Mar 27; 64(3):526-35. PubMed ID: 26928940
    [Abstract] [Full Text] [Related]

  • 38. Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study.
    Liu J, Masoudi FA, Spertus JA, Wang Q, Murugiah K, Spatz ES, Li J, Li X, Ross JS, Krumholz HM, Jiang L, China PEACE Collaborative Group.
    J Am Heart Assoc; 2015 Feb 23; 4(2):. PubMed ID: 25713293
    [Abstract] [Full Text] [Related]

  • 39. Effects of medication on cardiovascular events in the Japanese coronary artery disease (JCAD) study.
    Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R, JCAD Investigators.
    Circ J; 2007 Dec 23; 71(12):1835-40. PubMed ID: 18037732
    [Abstract] [Full Text] [Related]

  • 40. Effect of exposure to evidence-based pharmacotherapy on outcomes after acute myocardial infarction in older adults.
    Zuckerman IH, Yin X, Rattinger GB, Gottlieb SS, Simoni-Wastila L, Pierce SA, Huang TY, Shenolikar R, Stuart B.
    J Am Geriatr Soc; 2012 Oct 23; 60(10):1854-61. PubMed ID: 23003000
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.